Search

Fluorinated graphite/fluorocarbon (FCi/FEVE) composite coating was prepared by modifying FEVE with FGi, its adhesion, hardness, wear resistance and anti-corrosion performance were analyzed, and the wear resistant and anti- corrosion mechanism was discussed. The results show that the presence of the C-F bond in FCi not only increases the interface compatibility between the coating and the filler, further enhances the thermal stability of the composite coating, improves the adhesion strength and hardness, but also has excellent hydrophobic properties, which increases the contact angle of the coating surface from 84.5° to 102.0°. Electrochemical test result shows that the low frequency impedance modulus of FEVE composite coating modified by 1% FCi is 3.1 x 105 Ω • cm&#178, which is nearly one order of magnitude higher than that of pure FEVE coating, indicating that the composite coating has better anti-corrosion performance on the steel substrate. This is attributed to the hydrogen bond formed between FCi and the curing agent N75, which increases the dispersion of FCI in FEVE coating and can more effectively prevent the penetration of corrosive media. Friction test result shows that adding 1% FCi can reduce the friction coefficient of FEVE coating by 16.9% and the wear rate by 48.0%. FCi modification enhances the electrical insulation and hydrophobicity of FEVE coating, and plays the role of physical barrier, it can effectively prevent substrate from corrosion and crack expansion, so as to effectively improve the anti-corrosion and wear resistance of FCi/FEVE composite coating. [ABSTRACT FROM AUTHOR]

Objective: To analyze the correlation of methylation status of dachshund homolog 1 (DACH1) gene in tumor tissues with clinicopathological characteristics and prognosis of patients of esophageal cancer., Methods: Tumor tissue, paracancerous tissue and normal esophageal mucosal specimens of 104 patients with esophageal cancer were collected. Methylation-specific PCR was used to determine the methylation status of the DACH1 gene. Univariate analysis and multivariate Logistic regression model were used to analyze the correlation between DACH1 methylation status and clinical pathological characteristics of the patients. Kaplan-Meier survival curve was used to analyze the relationship between DACH1 methylation status and prognostic survival of patients., Results: The methylation rate of the DACH1 gene in esophageal cancer tumor tissue was 30.77% (32/104), which was higher than those in adjacent tissues (1.92%) and normal esophageal mucosa (0%) (P< 0.05). The methylation status of the DACH1gene in tumor tissues of patients did not correlate with the patient's age, gender, and pathological type (P> 0.05) but tumor differentiation, TNM staging, and lymph node metastasis(P< 0.05). The degree of tumor differentiation, TNM stage, and lymph node metastasis of patients are independent risk factors for the methylation status of the DACH1 gene. By March 2020, 89 of the 104 patients had died. Among them, the median survival foresophageal cancer patients with DACH1 gene methylation was 22 months, which was lower than 34 months of those without DACH1 methylation (P< 0.05)., Conclusion: Methylation of the DACH1 gene may be involved in the occurrence and progress of esophageal cancer. The degree of tumor differentiation, TNM stage, and lymph node metastasis of patients are independent risk factors for the methylation status of the DACH1 gene. Patients with esophageal cancer but unmethylated DACH1 gene have a longer prognostic survival.

Objective: The purpose of this study was to evaluate the mutation frequency of SLC26A4 gene in patients with enlarged vestibular aqueduct syndrome（EVAS） and/or Mondini dysplasia（MD）, so as to provide evidence for molecular diagnosis of deafness. Methods: In total, 74 patients with sensorineural hearing loss were included in this study. All patients underwent thin-layer CT examination of temporal bone. The coding exons of SLC26A4 were analyzed by second-generation sequencing in all subjects. Results: Among them, 37 patients with EVAS and MD（E+M group）, 28 patients with EVAS and without MD（E group）, and 9 patients with isolated MD（M group） were identified. In 74 cases, 66 cases（89.2%） were found to have mutation, including 64 cases（86.5%） of biallelic mutation and two cases（2.7%） of single allele mutation. The detection rate of SLC26A4 in different groups was statistically significant（ P <0.001）. The mutation rate in group M was significantly lower than that in Group E and E+M（ P <0.001）. In Group E, 27 cases（96.4%） had SLC26A4 biallelic mutations and one case（3.6%） had SLC26A4 single allele mutation, respectively; in Group E+M, 37 cases（100%） had SLC26A4 biallelic mutations; in group M, only one patient（11.1%） carried monoallelic mutations of the SLC26A4 gene. Conclusion: There are totally different pathogenesis in Chinese EVAS patients with or without MD, or isolated MD. Early clinical genetic diagnosis of patients with EVAS and/or MD helps to provide accurate information about the genetic causes of hearing loss, provide genetic counseling, and implement appropriate disease control and prevention measures. Next generation sequencing technology plays an increasingly important role in molecular diagnosis of deafness., Competing Interests: The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose., (Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery.)